<DOC>
	<DOCNO>NCT02406014</DOCNO>
	<brief_summary>This phase 4 , multi-centre , randomize , two group , open label , active control , parallel group , 17 week trial .</brief_summary>
	<brief_title>Efficacy Safety Ingenol Mebutate Gel 0.015 % Compared Diclofenac Sodium Gel 3 % Subjects With Actinic Keratoses Face Scalp</brief_title>
	<detailed_description>All subject qualify trial 4 8 clinically typical , visible discrete AK lesion within contiguous 25 cm2 treatment area face scalp . Eligible subject randomise 1:1 ratio follow treatment group : - Treatment Group A : Ingenol mebutate gel 0.015 % , daily 3 consecutive day first treatment course . At 8 week treatment initiation , subject present exist AKs newly emergent AKs treatment area receive one treatment course ingenol mebutate gel 0.015 % , daily 3 consecutive day . - Treatment Group B : Diclofenac sodium gel 3 % , ( 0.5 gram ) , twice daily 90 day .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1 . Following verbal write information trial , subject must provide informed consent document signing Informed Consent Form ( ICF ) prior trial related procedure 2 . Subjects 4 8 clinically typical , visible discrete AKs within contiguous 25 cmÂ² treatment area face scalp 1 . Location select treatment area : periorbital skin perioral skin/around nostril within 5 cm incompletely heal wound within 10 cm suspect BCC SCC neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>